Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 16;89(9):e0066520.
doi: 10.1128/IAI.00665-20. Epub 2021 Aug 16.

How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review

Mara Cruellas  1   2 , Alfonso Yubero  1   2 , María Zapata  1   2 , Eva M Galvez  3 , Marta Gascón  1   2 , Dolores Isla  1   2 , Rodrigo Lastra  1   2 , Luis Martínez-Lostao  2   4   5   6   7 , Maitane Ocariz  1   2 , Julián Pardo  2   8   9   10 , Ariel Ramírez  11 , Andrea Sesma  1   2 , Irene Torres-Ramón  1   2 , José Ramón Paño  2   12
Affiliations
Review

How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review

Mara Cruellas et al. Infect Immun. .

Abstract

Immunotherapy has become a new paradigm in oncology, improving outcomes for several types of cancer. However, there are some aspects about its management that remain uncertain. One of the key points that needs better understanding is the interaction between immunotherapy and gut microbiome and how modulation of the microbiome might modify the efficacy of immunotherapy. Consequently, the negative impact of systemic antibiotics and corticosteroids on the efficacy of immunotherapy needs to be clarified.

Keywords: antibiotics; cancer immunotherapy; corticosteroids; gut microbiota; immune checkpoint inhibitors; immunotherapy.

PubMed Disclaimer

References

    1. Johnson DB, Chandra S, Sosman JA. 2018. Immune checkpoint inhibitor toxicity in 2018. JAMA 320:1702–1703. doi: 10.1001/jama.2018.13995. - DOI - PubMed
    1. Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. 2019. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4:e000457–e000458. doi: 10.1136/esmoopen-2018-000457. - DOI - PMC - PubMed
    1. Galli G, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G. 2019. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer 132:72–78. doi: 10.1016/j.lungcan.2019.04.008. - DOI - PubMed
    1. Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. 2020. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist 25:55–63. doi: 10.1634/theoncologist.2019-0160. - DOI - PMC - PubMed
    1. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, BlumenscheinGR, Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators. 2017. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376:2415–2426. doi: 10.1056/NEJMoa1613493. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources